Skip to main content

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.

Publication ,  Journal Article
Shen, X; Parks, RJ; Montefiori, DC; Kirchherr, JL; Keele, BF; Decker, JM; Blattner, WA; Gao, F; Weinhold, KJ; Hicks, CB; Greenberg, ML ...
Published in: J Virol
April 2009

The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine development. We have identified serum antibodies from an HIV-infected subject that both were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 epitope. These MPER-specific antibodies were made 15 to 20 months following transmission and concomitantly with the development of autoantibodies. Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

April 2009

Volume

83

Issue

8

Start / End Page

3617 / 3625

Location

United States

Related Subject Headings

  • Virology
  • Time Factors
  • Neutralization Tests
  • Molecular Sequence Data
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41
  • HIV Antibodies
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shen, X., Parks, R. J., Montefiori, D. C., Kirchherr, J. L., Keele, B. F., Decker, J. M., … Tomaras, G. D. (2009). In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol, 83(8), 3617–3625. https://doi.org/10.1128/JVI.02631-08
Shen, Xiaoying, Robert J. Parks, David C. Montefiori, Jennifer L. Kirchherr, Brandon F. Keele, Julie M. Decker, William A. Blattner, et al. “In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.J Virol 83, no. 8 (April 2009): 3617–25. https://doi.org/10.1128/JVI.02631-08.
Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, et al. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol. 2009 Apr;83(8):3617–25.
Shen, Xiaoying, et al. “In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.J Virol, vol. 83, no. 8, Apr. 2009, pp. 3617–25. Pubmed, doi:10.1128/JVI.02631-08.
Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol. 2009 Apr;83(8):3617–3625.

Published In

J Virol

DOI

EISSN

1098-5514

Publication Date

April 2009

Volume

83

Issue

8

Start / End Page

3617 / 3625

Location

United States

Related Subject Headings

  • Virology
  • Time Factors
  • Neutralization Tests
  • Molecular Sequence Data
  • Humans
  • HIV-1
  • HIV Infections
  • HIV Envelope Protein gp41
  • HIV Antibodies
  • Female